The burgeoning popularity of retatrutide, initially for blood sugar control , is creating significant buzz within the British Isles, prompting a notable shift in peptide trends. Access these treatments remains a complex situation , with NHS coverage currently limited and independent providers offering therapy at a higher cost . Concerns are being r